What Is Claimed Is:

1. Use of (*S*)-bupropion that is at least 95% by weight enantiomerically pure in the manufacture of a medicament for treating a neurological disorder or a central nervous system disorder in a human being, wherein the medicament is to be orally administered in a dosage form one or two times per day to the human being, wherein the dosage form includes 80 mg to 120 mg of the (S)-bupropion, wherein the dosage form is more effective than administration of a dosage form including the same amount of (R)-bupropion in treating the same condition in the human being, and wherein the dosage form is substantially free of any active pharmaceutical agent other than (S)-bupropion.

2. A kit comprising a dosage form and a label, wherein the dosage form comprises (*S*)-bupropion that is at least 95% by weight enantiomerically pure, and the label states that the dosage form is to be orally administered one or two times per day to a human being for treating a condition in the human being, wherein the dosage form includes 80 mg to 120 mg of the (S)-bupropion, wherein the dosage form is more effective than administration of a dosage form including the same amount of (R)-bupropion in treating the same condition in the human being, and wherein the dosage form is substantially free of any active pharmaceutical agent other than (S)-bupropion.

3. The kit of claim 2, wherein the condition is a neurological disorder or a central nervous system disorder.

4. The kit of claim 3, wherein the human being is selected for having the condition.

5. The use of (*S*)-bupropion of claim 1, or the kit of any one of claims 2-4, wherein the (*S*)-bupropion is to be administered once daily.

6. The use of (*S*)-bupropion of claim 1, or the kit of any one of claims 2-4, wherein the (*S*)-bupropion is to be administered in two doses per day, and wherein the sum of the two doses per day is a daily dose.

7. The use of (*S*)-bupropion of any one of claims 1, 5, or 6, or the kit of any one of claims 2-6, wherein the (*S*)-bupropion is to be administered for at least 8 consecutive days.

8. The use of (*S*)-bupropion of any one of claims 1, 5, or 6, or the kit of any one of claims 2-6, wherein the (*S*)-bupropion is to be administered for at least 14 consecutive days.

9. The use of (*S*)-bupropion of any one of claims 1, 5, or 6, or the kit of any one of claims 2-6, wherein the (*S*)-bupropion is to be administered for at least 21 consecutive days.

10. The use of (*S*)-bupropion of any one of claims 1, 5, or 6, or the kit of any one of claims 2-6, wherein the (*S*)-bupropion is to be administered for at least 28 consecutive days.

11. The use of (*S*)-bupropion of any one of claims 1 or 5-10, or the kit of any one of claims 2-10, wherein the dosage form provides sustained release of the (*S*)-bupropion.

12. The use of (*S*)-bupropion of claim 11, or the kit of claim 11, wherein the dosage form is formulated to have a T_{max} of (*S*)-bupropion that is 2 hours to 4 hours.

13. The use of (*S*)-bupropion of any one of claims 1 or 5-12, or the kit of any one of claims 2-12, wherein the dosage form provides an AUC_{0-12} of (*S*)-bupropion in the human being that is at least about 300 ng·hr/mL.

14. The use of (*S*)-bupropion of any one of claims 1 or 5-12, or the kit of any one of claims 2-12, wherein the dosage form provides an AUC_{0-12} of (*S*)-bupropion in the human being that is at least about 400 ng·hr/mL.

15. The use of (*S*)-bupropion of any one of claims 1 or 5-14, or the kit of any one of claims 2-14, wherein the dosage form provides an AUC_{0-12} of (*S*)-bupropion in the human being that is 500 ng·hr/mL to 900 ng·hr/mL.

16. The use of (*S*)-bupropion of any one of claims 1 or 5-15, or the kit of any one of claims 2-15, wherein the dosage form provides a C_{max} of (*S*)-bupropion in the human being that is 60 ng/mL to 140 ng/mL.